Regorafenib monotherapy (CORRECT-style; ReDOS escalation preferred)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-REGORAFENIB |
|---|
| ID | REG-REGORAFENIB |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-COLON-2024 SRC-NCCN-COLON-2025 |
Notes
CORRECT trial (Grothey 2013): 3L+ chemo-refractory mCRC — regorafenib vs placebo improved mOS 6.4 vs 5.0 mo (HR 0.77). Modest absolute benefit. ReDOS dose-escalation strategy (Bekaii-Saab 2019) — start 80 mg, escalate weekly to 160 mg if tolerated — preserves efficacy while substantially improving tolerability + treatment continuation rate. CONCUR (Asian patients) confirmed activity. CORRECT and SUNLIGHT (TAS-102+bev) outcomes broadly similar; SUNLIGHT now preferred 3L+ where accessible due to better tolerability profile. Hepatotoxicity surveillance critical — weekly LFT cycle 1, then q2w.
Used By
Indication
IND-CRC-METASTATIC-3L-REGORAFENIB- IND-CRC-METASTATIC-3L-REGORAFENIBIND-CRC-METASTATIC-3L-TAS102-BEV- IND-CRC-METASTATIC-3L-TAS102-BEV